Welcome to our dedicated page for Bio-Path Holdings news (Ticker: BPTH), a resource for investors and traders seeking the latest updates and insights on Bio-Path Holdings stock.
Bio-Path Holdings Inc. (NASDAQ: BPTH) is a pioneering biotechnology company focused on developing innovative therapeutic products through its proprietary DNAbilize® technology. This technology enables the delivery of nucleic acid drugs throughout the human body via simple intravenous infusion. Bio-Path's primary focus is on oncology, aiming to provide effective treatments for various forms of cancer.
The company's lead product candidate, prexigebersen (BP1001), is currently in Phase II clinical trials for Acute Myeloid Leukemia (AML) in combination with low-dose cytarabine (LDAC) and decitabine. Additionally, Bio-Path is exploring prexigebersen's potential in combination with dasatinib for patients with blast-phase and accelerated-phase Chronic Myeloid Leukemia (CML).
Another key candidate, BP1002, targets the Bcl-2 protein, which plays a crucial role in cell survival for many cancers. BP1002 is being evaluated for its effectiveness against lymphoma and solid tumors, offering hope for venetoclax-resistant AML patients. The company's technological advantage lies in its DNAbilize® platform, a liposomal antisense DNA method that significantly improves oligonucleotide therapeutics' delivery and efficacy.
Bio-Path Holdings continues to expand its pipeline with additional candidates such as BP1003, a STAT3 antisense oligodeoxynucleotide, and BP1001-A, a modification designed for solid tumors. These developments emphasize the company's commitment to addressing unmet medical needs in oncology.
Recently, Bio-Path has made significant strides in its clinical programs, receiving positive feedback from the U.S. FDA and advancing its trials at renowned institutions including Weill Cornell Medical College and The University of Texas MD Anderson Cancer Center. The company maintains a robust intellectual property portfolio to protect its innovative DNAbilize® platform.
For investors and stakeholders, Bio-Path Holdings represents a forward-thinking entity with a strategic focus on developing novel RNAi nanoparticle drugs. The company's advancements in the clinical and preclinical stages underline its potential to make substantial contributions to cancer treatment paradigms.
Bio-Path Holdings (NASDAQ:BPTH) reported positive preclinical study results for BP1001-A as a potential treatment for obesity in Type 2 diabetes patients. The studies demonstrated that BP1001-A enhances insulin sensitivity by downregulating Grb2 protein expression, which helps lower blood glucose levels.
Key findings showed that BP1001-A reduced Grb2 protein expression in myoblast cells and increased phosphorylated AKT and FOXO-1 levels in myoblast and hepatoma cells with insulin present. The company has initiated animal studies and plans to begin a first-in-human Phase 1 clinical trial in 2025 to validate safety, measure pharmacokinetics, and establish dosing for potential pivotal trials.
Stonegate Capital Partners has updated its coverage on Bio-Path Holdings (NASDAQ: BPTH) for the third quarter of 2024. The detailed announcement includes downloadable images, bios, and more information. For the complete announcement, click the image above.
Bio-Path Holdings (NASDAQ:BPTH) has outlined its strategic focus on developing BP1001-A as a potential treatment for obesity in Type 2 diabetes patients. The company's decision is based on scientific evidence suggesting that downregulating growth factor receptor-bound protein 2 (Grb2) could help lower blood glucose levels by affecting insulin signaling.
The company is conducting confirmatory preclinical studies and plans to complete IND-enabling testing in Q4 2024. Simultaneously, Bio-Path announced the discontinuation of its Phase 1 clinical trial of BP1002 for refractory/relapsed lymphoma and chronic lymphocytic leukemia due to enrollment challenges in these niche indications.
Bio-Path Holdings reported Q3 2024 financial results with a net loss of $2.1 million ($0.70 per share), compared to $3.2 million loss in Q3 2023. The company initiated a new obesity program using its DNAbilize® technology, marking its first non-oncology application. Research and development expenses decreased to $1.3 million from $2.3 million year-over-year. The company completed enrollment for the third dosing cohort of BP1002 in venetoclax-resistant AML patients ahead of schedule. In October, Bio-Path closed a $4.0 million private placement. Cash position stood at $0.6 million as of September 30, 2024.
Bio-Path Holdings (NASDAQ: BPTH) announced it will host a conference call and audio webcast on November 15, 2024, at 8:30 a.m. ET to discuss third quarter 2024 financial results and provide a business overview. The company develops DNAbilize®, an RNAi nanoparticle drug technology administered through intravenous transfusion. Their pipeline includes prexigebersen (BP1001) in Phase 2 for blood cancers, BP1001-A in Phase 1/1b for solid tumors, and BP1002 targeting Bcl-2 protein for blood cancers and solid tumors. They're also preparing an IND filing for BP1003, a STAT3 inhibitor.
Bio-Path Holdings (NASDAQ:BPTH) has closed a $4.0 million private placement priced at-the-market under Nasdaq rules. The offering included the issuance of 4,597,702 shares of common stock (or equivalents), series A warrants for up to 6,407,657 shares, and short-term series B warrants for up to 6,407,657 shares at $0.87 per share. Both warrant types have an exercise price of $1.00 per share.
The company plans to use the net proceeds for working capital and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent. Additionally, certain outstanding warrants from June 2024 were cancelled upon closing of this placement.
Bio-Path Holdings (NASDAQ:BPTH) has announced a $4.0 million private placement priced at-the-market under Nasdaq rules. The company will issue and sell 4,597,702 shares of common stock (or equivalents), along with series A and B warrants to purchase additional shares. The purchase price is set at $0.87 per share, with warrants exercisable at $1.00 per share. The offering is expected to close around October 10, 2024.
H.C. Wainwright & Co. is acting as the exclusive placement agent. Bio-Path intends to use the net proceeds for working capital and general corporate purposes. The securities are being offered under Section 4(a)(2) of the Securities Act and have not been registered. The company has agreed to file a resale registration statement for these securities.
Bio-Path Holdings (NASDAQ:BPTH) has announced two significant developments:
1. Initiation of a therapeutic program to develop BP1001-A for treating obesity and related metabolic diseases, marking the first non-cancer application of their DNAbilize® technology.
2. Completion of enrollment in the third dosing cohort of the ongoing Phase 1/1b clinical trial evaluating BP1002 for refractory/relapsed acute myeloid leukemia (AML) patients, including venetoclax-resistant patients.
The company expects to begin preclinical studies for BP1001-A in Q4 2024, targeting insulin resistance. The rapid enrollment in the BP1002 trial highlights the urgent need for new treatment options in AML.
Bio-Path Holdings (NASDAQ:BPTH) announced a publication in Biomedicines highlighting the therapeutic potential of BP1003 in various cancer types. The article, titled 'BP1003 Decreases STAT3 Expression and Its Pro-Tumorigenic Functions in Solid Tumors and the Tumor Microenvironment,' describes the broad anti-tumor effect of BP1003 in preclinical solid tumor models including breast, ovarian, and pancreatic cancer.
BP1003 is a neutral liposome incorporated with a nuclease resistant P-ethoxy antisense oligodeoxynucleotide targeting the STAT3 mRNA. The company believes BP1003 has the potential to enhance the efficacy of current standard of care chemotherapies in a broad range of difficult to treat cancers. This publication marks Bio-Path's twenty-second peer-reviewed article supporting its DNAbilize® technology.
Stonegate Capital Partners has updated its coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for the second quarter of 2024. This update provides investors with fresh insights into the company's performance and market position. Bio-Path Holdings is a biotechnology company focused on developing innovative therapies using its proprietary DNAbilize® antisense RNAi nanoparticle technology. The update from Stonegate Capital Partners, a respected financial research firm, is likely to offer valuable analysis on Bio-Path's recent developments, financial health, and future prospects in the competitive biotech sector.
FAQ
What is the current stock price of Bio-Path Holdings (BPTH)?
What is the market cap of Bio-Path Holdings (BPTH)?
What is Bio-Path Holdings Inc. known for?
What is DNAbilize® technology?
What is prexigebersen (BP1001)?
What is BP1002 and what does it target?
Which institutions are involved in Bio-Path's clinical trials?
What is the potential advantage of BP1002 over current treatments?
What are the main benefits of DNAbilize® technology for patients?
What is BP1003 and what does it target?
How does Bio-Path Holdings protect its innovations?
How can investors get more information about Bio-Path Holdings?
